Millions of Patients. No Real Cure. Until Now.

Lamina Therapeutics regenerates bone and cartilage simultaneously with Lamina.One®: the world's first fully synthetic, animal-free implant combining a biodegradable medical device with stem cells, authorized for Phase I clinical trial by EMA and ANSM.

Today, millions of osteoarthritis patients fall into a gap between rheumatology and orthopedics. Treated symptomatically for years, they often end up with no option left but joint replacement, a heavy, invasive, and irreversible surgery. There is currently no treatment that actually repairs the damaged tissue. Lamina Therapeutics was built to change that for the patient.

Founded in 2020 as a spin-off from INSERM and the University of Strasbourg (UMR1260 Regenerative NanoMedicine) by Prof. Nadia Benkirane-Jessel, built on three licensed patent families, we are developing the next generation of regenerative orthopedic solutions. In just four years, our team went from early-stage intellectual property to full clinical trial authorization, a remarkable milestone in one of medicine's most demanding regulatory landscapes.

Our flagship product, Lamina.One®, is the world's first to simultaneously regenerate subchondral bone and cartilage in a single, minimally invasive procedure. It works in two complementary compartments: a biodegradable medical device supports bone regeneration, while autologous stem cells drawn from the patient's own bone marrow, or in the future allogeneic stem cells to make the treatment more accessible for ageing patients, are mixed with a hydrogel directly before implantation to drive cartilage repair. The result is a fully synthetic, entirely animal-free implant delivered as a ready-to-use kit in one single surgical step, with no harvesting of healthy tissue and no need for a second procedure.

After rigorous preclinical validation across in vitro studies, rodent and sheep models, and a successful cadaveric feasibility study, we secured EMA and ANSM authorization for a first-in-human Phase I clinical trial in Strasbourg. This makes Lamina.One® the only combined Advanced Therapy Medicinal Product (cATMP) in the world to have received this authorization for osteochondral knee focal lesions repair. We have also built a strong multinational consortium across Europe to conduct a broad clinical study and accelerate the path to patients.

Patients are actively asking for this treatment, surgeons are convinced, the scientific community is behind it, regulatory authorities have granted their authorization, the solution is simple to deliver and cost-effective for healthcare systems, and the unmet medical need is enormous. Everything is aligned, and we are now raising 10 million euros in a Series A to bring it to the patients who need it most.